Breaking News Instant updates and real-time market news.

AGIO

Agios Pharmaceuticals

$58.12

3.99 (7.37%)

07:32
12/26/17
12/26
07:32
12/26/17
07:32

Agios Pharmaceuticals submits new FDA application for Ivosidenib

Agios Pharmaceuticals announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for ivosidenib, an investigational oral treatment for patients with relapsed or refractory acute myeloid leukemia and an isocitrate dehydrogenase-1 mutation. Agios has requested priority review for the application, which, if granted, could result in a six-month review process. The NDA is supported by data from the ongoing Phase 1 dose-escalation and expansion study of ivosidenib in patients with advanced hematologic malignancies and an IDH1 mutation. Ivosidenib is wholly owned by Agios. The FDA has a 60-day filing review period to determine whether the NDA is complete and acceptable for filing.

AGIO Agios Pharmaceuticals
$58.12

3.99 (7.37%)

08/02/17
08/02/17
UPGRADE
Target $80

Outperform
Agios Pharmaceuticals upgraded to Outperform at Leerink
As previously reported, Leerink analyst Michael Schmidt upgraded Agios Pharmaceuticals to Outperform from Market Perform based on his higher-level conviction regarding the commercial opportunity for its IDH inhibitors Idhifa and ivosidenib in acute myeloid leukemia following Idhifa FDA-approval and his recent checks indicating a high degree of enthusiasm for these agents in the physician community pointing to potential good initial uptake. The analyst also raised his price target on the shares to $80 from $50.
08/02/17
08/02/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pfizer (PFE) upgraded to Outperform from Market Perform at BMO Capital with analyst Alex Arfaei saying he expects "positive updates" on the company's pipeline that could improve investors' view on the company. 2. Royal Caribbean (RCL) upgraded to Neutral from Sell at Goldman Sachs with analyst Stephen Grambling citing "strong" leisure trends following the company's better than expected second quarter results. 3. Illumina (ILMN) upgraded to Equal-Weight from Underweight at First Analysis with analyst Joseph Munda saying concerns regarding sequencing overcapacity in the marketplace and the potential rate of adoption for NovaSeq are diminishing based on performance in the quarter. 4. Agios Pharmaceuticals (AGIO) upgraded to Outperform from Market Perform at Leerink with analyst Michael Schmidt citing his higher-level conviction regarding the commercial opportunity for its IDH inhibitors Idhifa and ivosidenib in acute myeloid leukemia following Idhifa FDA-approval and his recent checks indicating a high degree of enthusiasm for these agents in the physician community pointing to potential good initial uptake. 5. Sonoco Products (SON) upgraded to Hold from Sell at Vertical Research with analyst Chip Dillion citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/14/17
RBCM
09/14/17
INITIATION
Target $78
RBCM
Outperform
Agios Pharmaceuticals initiated with an Outperform at RBC Capital
RBC Capital analyst Kennen MacKay initiated Agios Pharmaceuticals with an Outperform and a $78 price target.
09/18/17
JPMS
09/18/17
NO CHANGE
Target $76
JPMS
Overweight
Agios Pharmaceuticals price target raised to $76 from $71 at JPMorgan
JPMorgan analyst Anupam Rama raised his price target for Agios Pharmaceuticals to $76 after conducting a survey of 26 U.S. hematologists. The survey indicated there is broader awareness of Idhifa, "encouraging views" on its efficacy and "rapid uptake," Rama tells investors in a research note. The analyst reiterates an Overweight rating on Agios.

TODAY'S FREE FLY STORIES

GRUB

GrubHub

$103.64

-0.145 (-0.14%)

05:58
05/22/18
05/22
05:58
05/22/18
05:58
Recommendations
GrubHub analyst commentary  »

GrubHub price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 12

    Jun

ZTCOY

ZTE Corp.

$0.00

(0.00%)

05:58
05/22/18
05/22
05:58
05/22/18
05:58
Periodicals
U.S., China reach broad outline on deal to settle ZTE controversy, WSJ reports »

The U.S. and China have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

HURN

Huron

$38.30

0.65 (1.73%)

05:57
05/22/18
05/22
05:57
05/22/18
05:57
Conference/Events
Huron management to meet with William Blair »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 12

    Jun

TOL

Toll Brothers

$43.60

0.43 (1.00%)

05:57
05/22/18
05/22
05:57
05/22/18
05:57
Earnings
Toll Brothers reports Q2 EPS 72c, consensus 76c »

Reports Q2 revenue $1.6B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

WWE

WWE

$57.86

6.37 (12.37%)

05:56
05/22/18
05/22
05:56
05/22/18
05:56
Conference/Events
WWE management to meet with MKM Partners »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

WD

Walker & Dunlop

$56.10

1.07 (1.94%)

05:55
05/22/18
05/22
05:55
05/22/18
05:55
Conference/Events
Walker & Dunlop management to meet with JMP Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    May

  • 31

    May

BUD

AB InBev

05:55
05/22/18
05/22
05:55
05/22/18
05:55
Upgrade
AB InBev rating change  »

AB InBev upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMM

3M

$201.75

2.8 (1.41%)

, BAYRY

Bayer

$0.00

(0.00%)

05:55
05/22/18
05/22
05:55
05/22/18
05:55
Conference/Events
American Thoracic Society to hold a conference »

ATS 2018 will be held in…

MMM

3M

$201.75

2.8 (1.41%)

BAYRY

Bayer

$0.00

(0.00%)

BDX

Becton Dickinson

$228.74

3.73 (1.66%)

BIIB

Biogen

$277.69

-2.66 (-0.95%)

STEM

Ticker changed to MBOT

$0.00

(0.00%)

TEVA

Teva

$21.09

-0.14 (-0.66%)

UTHR

United Therapeutics

$104.12

-2.2 (-2.07%)

VCYT

Veracyte

$6.45

(0.00%)

VRTX

Vertex

$156.15

-1.09 (-0.69%)

NBRV

Nabriva Therapeutics

$4.54

-0.89 (-16.39%)

GILD

Gilead

$67.63

-0.38 (-0.56%)

GSK

GlaxoSmithKline

$40.05

0.005 (0.01%)

HRC

Hill-Rom

$90.70

0.12 (0.13%)

INNV

Innovus Pharmaceuticals

$0.00

(0.00%)

DNA

Bought by RHHBY

$0.00

(0.00%)

CELG

Celgene

$74.69

-3.7 (-4.72%)

JAZZ

Jazz Pharmaceuticals

$166.01

-1.59 (-0.95%)

ISRG

Intuitive Surgical

$463.18

4.3 (0.94%)

INSM

Insmed

$26.34

-2.16 (-7.58%)

REGN

Regeneron

$296.58

-5.29 (-1.75%)

OCX

OncoCyte

$2.50

-0.05 (-1.96%)

FGEN

FibroGen

$52.55

1.45 (2.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 24

    May

  • 30

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 12

    Jun

  • 13

    Jun

  • 13

    Jun

  • 14

    Jun

  • 16

    Jun

  • 25

    Jun

  • 26

    Jun

  • 11

    Aug

  • 20

    Oct

  • 20

    Dec

CCJ

Cameco

$11.38

0.015 (0.13%)

05:54
05/22/18
05/22
05:54
05/22/18
05:54
Downgrade
Cameco rating change  »

Cameco downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TER

Teradyne

$38.17

0.77 (2.06%)

05:54
05/22/18
05/22
05:54
05/22/18
05:54
Conference/Events
Teradyne management to meet with Craig Hallum »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 30

    May

RTN

Raytheon

$213.95

2.88 (1.36%)

05:54
05/22/18
05/22
05:54
05/22/18
05:54
Downgrade
Raytheon rating change  »

Raytheon downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYRS

Syros Pharmaceuticals

$11.96

-0.41 (-3.31%)

05:54
05/22/18
05/22
05:54
05/22/18
05:54
Conference/Events
Syros Pharmaceuticals management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

SPSC

SPS Commerce

$71.88

0.11 (0.15%)

05:53
05/22/18
05/22
05:53
05/22/18
05:53
Conference/Events
SPS Commerce management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    May

  • 29

    May

  • 12

    Jun

RDCM

Radcom

$19.65

0.25 (1.29%)

05:52
05/22/18
05/22
05:52
05/22/18
05:52
Conference/Events
Radcom management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    May

  • 24

    May

  • 29

    May

INFO

IHS Markit

$51.60

0.13 (0.25%)

05:52
05/22/18
05/22
05:52
05/22/18
05:52
Upgrade
IHS Markit rating change  »

IHS Markit upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FITB

Fifth Third

$30.89

-2.66 (-7.93%)

05:51
05/22/18
05/22
05:51
05/22/18
05:51
Upgrade
Fifth Third rating change  »

Fifth Third upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QTM

Quantum

$3.62

-0.06 (-1.63%)

05:51
05/22/18
05/22
05:51
05/22/18
05:51
Conference/Events
Quantum management to meet with Lake Street »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 29

    May

FITB

Fifth Third

$30.89

-2.66 (-7.93%)

05:51
05/22/18
05/22
05:51
05/22/18
05:51
Upgrade
Fifth Third rating change  »

Fifth Third upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OTEX

OpenText

$34.10

0.1 (0.29%)

05:51
05/22/18
05/22
05:51
05/22/18
05:51
Conference/Events
OpenText management to meet with Benchmark »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

NVEE

NV5 Global

$60.60

0.6 (1.00%)

05:50
05/22/18
05/22
05:50
05/22/18
05:50
Conference/Events
NV5 Global management to meet with Lake Street »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

  • 09

    Jun

  • 12

    Jun

  • 13

    Jun

M

Macy's

$34.60

0.63 (1.85%)

05:49
05/22/18
05/22
05:49
05/22/18
05:49
Upgrade
Macy's rating change  »

Macy's upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCR

NCR Corp.

$31.30

0.11 (0.35%)

05:49
05/22/18
05/22
05:49
05/22/18
05:49
Conference/Events
NCR Corp. management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

ONCE

Spark Therapeutics

$73.03

-3.69 (-4.81%)

, PFE

Pfizer

$35.79

0.15 (0.42%)

05:44
05/22/18
05/22
05:44
05/22/18
05:44
Hot Stocks
Spark Therapeutics, Pfizer announce data SPK-9001 ongoing Phase 1/2 trial »

Spark Therapeutics (ONCE)…

ONCE

Spark Therapeutics

$73.03

-3.69 (-4.81%)

PFE

Pfizer

$35.79

0.15 (0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 10

    Sep

FMC

FMC Corporation

$91.30

-0.22 (-0.24%)

05:41
05/22/18
05/22
05:41
05/22/18
05:41
Hot Stocks
FMC Corporation awarded contract for two fertilizer plants in India »

TechnipFMC, in consortium…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

S

Sprint

$5.17

0.05 (0.98%)

05:40
05/22/18
05/22
05:40
05/22/18
05:40
Hot Stocks
Sprint partners with Scopeworker on multi-billion dollar 5G depoloyment »

Scopeworker announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.